JP2017514838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514838A5 JP2017514838A5 JP2016565398A JP2016565398A JP2017514838A5 JP 2017514838 A5 JP2017514838 A5 JP 2017514838A5 JP 2016565398 A JP2016565398 A JP 2016565398A JP 2016565398 A JP2016565398 A JP 2016565398A JP 2017514838 A5 JP2017514838 A5 JP 2017514838A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- amino
- methyl
- disease
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 30
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 10
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- -1 3-((2-amino-4- (pentylamino) -5H-pyrrolo [3,2-d] pyrimidin-5-yl) methyl) -4-methoxyphenyl Chemical group 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000009621 actinic keratosis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- DAMMDMFUWSPYOK-FQEVSTJZSA-N (2S)-1-[[4-[[2-amino-4-(pentylamino)pyrrolo[3,2-d]pyrimidin-5-yl]methyl]-3-methoxyphenyl]methyl]pyrrolidine-2-carboxylic acid Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(CN1[C@@H](CCC1)C(=O)O)C=C2)OC)NCCCCC DAMMDMFUWSPYOK-FQEVSTJZSA-N 0.000 claims description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 4
- WPXQRVLICLGUCL-UHFFFAOYSA-N N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC WPXQRVLICLGUCL-UHFFFAOYSA-N 0.000 claims description 4
- JPMCLZUWKYUICG-UHFFFAOYSA-N N1N=NN=C1CCC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound N1N=NN=C1CCC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC JPMCLZUWKYUICG-UHFFFAOYSA-N 0.000 claims description 4
- YAPMMXHTJBSLQT-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C(=O)O)C=CC2OC)NCCCCC YAPMMXHTJBSLQT-UHFFFAOYSA-N 0.000 claims description 4
- DGBUFDBJFRAKLI-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)NCCCCC DGBUFDBJFRAKLI-UHFFFAOYSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- YATPCANSKUAXLN-HXUWFJFHSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CN1[C@H](CCC1)C(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CN1[C@H](CCC1)C(=O)O)C=CC2OC)NCCCCC YATPCANSKUAXLN-HXUWFJFHSA-N 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- XBPWCXCQZZVVDJ-UHFFFAOYSA-N C(CCCCC)NC=1C2=C(N=C(N1)N)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC Chemical compound C(CCCCC)NC=1C2=C(N=C(N1)N)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC XBPWCXCQZZVVDJ-UHFFFAOYSA-N 0.000 claims description 2
- ZMXZKMDODWPMFT-UHFFFAOYSA-N COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=C(C=C1)C1=NN=NN1 Chemical compound COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=C(C=C1)C1=NN=NN1 ZMXZKMDODWPMFT-UHFFFAOYSA-N 0.000 claims description 2
- BIQPCKWQIOGLRO-UHFFFAOYSA-N COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=CC(=C1)C1=NN=NN1 Chemical compound COC1=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C=CC(=C1)C1=NN=NN1 BIQPCKWQIOGLRO-UHFFFAOYSA-N 0.000 claims description 2
- LERPKRPELMLJGL-UHFFFAOYSA-N FC(C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC)(C1=NN=NN1)F Chemical compound FC(C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC)(C1=NN=NN1)F LERPKRPELMLJGL-UHFFFAOYSA-N 0.000 claims description 2
- MHHIXFORUFMUNC-UHFFFAOYSA-N N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical class N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC MHHIXFORUFMUNC-UHFFFAOYSA-N 0.000 claims description 2
- ZJCMDZVSGDFLGB-KRWDZBQOSA-N N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC Chemical compound N1N=NN=C1C(C)(C)C=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC ZJCMDZVSGDFLGB-KRWDZBQOSA-N 0.000 claims description 2
- LDGLRXLZQXFAQH-HNNXBMFYSA-N N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCC)N)C1)OC Chemical compound N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCC)N)C1)OC LDGLRXLZQXFAQH-HNNXBMFYSA-N 0.000 claims description 2
- QTGPSLBHJHDMAA-INIZCTEOSA-N N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC Chemical compound N1N=NN=C1CC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)N[C@H](CO)CCCC)N)C1)OC QTGPSLBHJHDMAA-INIZCTEOSA-N 0.000 claims description 2
- VHPPHGRMEQLRTI-UHFFFAOYSA-N N1N=NN=C1COC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC Chemical compound N1N=NN=C1COC=1C=CC(=C(CN2C=CC=3N=C(N=C(C32)NCCCCC)N)C1)OC VHPPHGRMEQLRTI-UHFFFAOYSA-N 0.000 claims description 2
- YEGDWVRORNWXCA-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(OCC(=O)O)C=C2)OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=C(OCC(=O)O)C=C2)OC)NCCCCC YEGDWVRORNWXCA-UHFFFAOYSA-N 0.000 claims description 2
- LNDUPESSOYMSJP-HNNXBMFYSA-N NC=1N=C(C2=C(N1)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC2=C(C=CC(=C2)C2=NN=NN2)OC)N[C@H](CO)CCCC LNDUPESSOYMSJP-HNNXBMFYSA-N 0.000 claims description 2
- XNZLVNCYIWAOFE-VQHVLOKHSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)/C=C/C(=O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)/C=C/C(=O)O)NCCCCC XNZLVNCYIWAOFE-VQHVLOKHSA-N 0.000 claims description 2
- YIHAVTSAPRGDNW-INIZCTEOSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CC(=O)O)N[C@H](CO)CCCC YIHAVTSAPRGDNW-INIZCTEOSA-N 0.000 claims description 2
- YVHVMLRGFSLIND-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)NCCCCC YVHVMLRGFSLIND-UHFFFAOYSA-N 0.000 claims description 2
- NNOMZLJTXKTXQJ-KRWDZBQOSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)N[C@H](CO)CCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)CCC(=O)O)N[C@H](CO)CCCC NNOMZLJTXKTXQJ-KRWDZBQOSA-N 0.000 claims description 2
- AJLRGBCKWKXKJK-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)P(O)(O)=O)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(C=CC2OC)P(O)(O)=O)NCCCCC AJLRGBCKWKXKJK-UHFFFAOYSA-N 0.000 claims description 2
- MKYWYRKMBXGWJU-UHFFFAOYSA-N NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CC=1N=NN(N1)CC(=O)O)C=CC2OC)NCCCCC Chemical compound NC=1N=C(C2=C(N1)C=CN2CC=2C=C(CC=1N=NN(N1)CC(=O)O)C=CC2OC)NCCCCC MKYWYRKMBXGWJU-UHFFFAOYSA-N 0.000 claims description 2
- FVQOAYDCQJAKTH-WOJBJXKFSA-N NC=1N=C(C2=C(N=1)C=CN2CC=1C=C(C=CC=1OC)CC[C@H](C[C@H](CC(=O)O)O)O)NCCCCC Chemical compound NC=1N=C(C2=C(N=1)C=CN2CC=1C=C(C=CC=1OC)CC[C@H](C[C@H](CC(=O)O)O)O)NCCCCC FVQOAYDCQJAKTH-WOJBJXKFSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 description 14
- 238000000034 method Methods 0.000 description 8
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987321P | 2014-05-01 | 2014-05-01 | |
| US61/987,321 | 2014-05-01 | ||
| PCT/US2015/028264 WO2015168269A1 (en) | 2014-05-01 | 2015-04-29 | Compounds and compositions as toll-like receptor 7 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514838A JP2017514838A (ja) | 2017-06-08 |
| JP2017514838A5 true JP2017514838A5 (enExample) | 2018-04-05 |
| JP6484253B2 JP6484253B2 (ja) | 2019-03-13 |
Family
ID=53284501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565398A Active JP6484253B2 (ja) | 2014-05-01 | 2015-04-29 | Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9902730B2 (enExample) |
| EP (1) | EP3137470B1 (enExample) |
| JP (1) | JP6484253B2 (enExample) |
| KR (1) | KR102139847B1 (enExample) |
| CN (1) | CN106232603B (enExample) |
| AP (1) | AP2016009485A0 (enExample) |
| AR (1) | AR100244A1 (enExample) |
| AU (1) | AU2015253215B2 (enExample) |
| BR (1) | BR112016025423A2 (enExample) |
| CA (1) | CA2946408C (enExample) |
| CL (1) | CL2016002751A1 (enExample) |
| CR (1) | CR20160512A (enExample) |
| CU (1) | CU24401B1 (enExample) |
| DO (1) | DOP2016000295A (enExample) |
| EA (1) | EA030603B1 (enExample) |
| ES (1) | ES2877050T3 (enExample) |
| GT (1) | GT201600233A (enExample) |
| IL (1) | IL248347B (enExample) |
| MX (1) | MX362341B (enExample) |
| NI (1) | NI201600164A (enExample) |
| NZ (1) | NZ724792A (enExample) |
| PE (1) | PE20170325A1 (enExample) |
| PH (1) | PH12016501966B1 (enExample) |
| PL (1) | PL3137470T3 (enExample) |
| PT (1) | PT3137470T (enExample) |
| SG (1) | SG11201608161VA (enExample) |
| SV (1) | SV2016005311A (enExample) |
| TW (1) | TWI666212B (enExample) |
| UY (1) | UY36103A (enExample) |
| WO (1) | WO2015168269A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459058B (zh) | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | 作为toll-样受体7激动剂的化合物和组合物 |
| CN110759916B (zh) | 2014-08-15 | 2021-02-19 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| KR102394917B1 (ko) | 2015-03-04 | 2022-05-09 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| CR20180109A (es) * | 2015-07-20 | 2018-05-03 | Genzyme Corp | Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r) |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043377A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| CN106727768A (zh) * | 2017-02-06 | 2017-05-31 | 灞卞嘲 | 一种治疗子宫内膜炎的药物组合物 |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US12128047B2 (en) * | 2018-05-25 | 2024-10-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist and pharmaceutical combination thereof for treating lung cancer |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| CN113271938A (zh) * | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| ES2960987T3 (es) | 2019-04-12 | 2024-03-07 | Riboscience Llc | Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP3980423A1 (en) * | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| MY208114A (en) | 2019-09-30 | 2025-04-16 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| EP4097102A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| CN115151548A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20230140430A1 (en) | 2020-01-27 | 2023-05-04 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132602A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| JP2023512230A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしてのＣ３置換１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| US12485123B2 (en) | 2020-01-27 | 2025-12-02 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists |
| KR20220132592A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| CN115210235A (zh) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| KR20220132601A (ko) * | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0530537B1 (en) | 1991-08-12 | 1997-01-08 | Takeda Chemical Industries, Ltd. | Condensed pyrimidine derivatives, their production and use as antitumor agents |
| JPH10501532A (ja) | 1994-06-09 | 1998-02-10 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗物質 |
| WO2000068213A1 (en) | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Substituted bicyclic compounds |
| CN1918158B (zh) * | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP1728792A4 (en) * | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
| WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| MXPA06013996A (es) | 2004-06-02 | 2007-02-08 | Takeda Pharmaceutical | Compuesto heterociclico fusionado. |
| UA91508C2 (ru) * | 2004-06-02 | 2010-08-10 | Такеда Фармасьютикал Компани Лимитед | Конденсированное гетероциклическое соединение |
| RU2383545C2 (ru) | 2005-03-15 | 2010-03-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| WO2007034917A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| ES2541434T3 (es) * | 2007-06-29 | 2015-07-20 | Gilead Sciences, Inc. | Derivados de purina y su uso como moduladores del receptor de tipo Toll 7 |
| MX2010008719A (es) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2011140338A1 (en) | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| WO2011162515A2 (en) | 2010-06-23 | 2011-12-29 | Hanmi Holdings Co. , Ltd. | Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity |
| WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| KR102280595B1 (ko) * | 2012-10-10 | 2021-07-22 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체 |
| CN106459058B (zh) | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | 作为toll-样受体7激动剂的化合物和组合物 |
| TW201632515A (zh) | 2015-01-23 | 2016-09-16 | 協友股份有限公司 | 經取代之吡唑吡唑衍生物及其作爲除草劑的用途 |
-
2015
- 2015-04-29 KR KR1020167030101A patent/KR102139847B1/ko not_active Expired - Fee Related
- 2015-04-29 UY UY0001036103A patent/UY36103A/es not_active Application Discontinuation
- 2015-04-29 NZ NZ724792A patent/NZ724792A/en not_active IP Right Cessation
- 2015-04-29 CA CA2946408A patent/CA2946408C/en not_active Expired - Fee Related
- 2015-04-29 CN CN201580021618.9A patent/CN106232603B/zh active Active
- 2015-04-29 AU AU2015253215A patent/AU2015253215B2/en not_active Ceased
- 2015-04-29 PE PE2016002146A patent/PE20170325A1/es unknown
- 2015-04-29 EP EP15727098.4A patent/EP3137470B1/en active Active
- 2015-04-29 US US15/307,525 patent/US9902730B2/en active Active
- 2015-04-29 BR BR112016025423A patent/BR112016025423A2/pt not_active IP Right Cessation
- 2015-04-29 CU CU2016000160A patent/CU24401B1/es unknown
- 2015-04-29 ES ES15727098T patent/ES2877050T3/es active Active
- 2015-04-29 CR CR20160512A patent/CR20160512A/es unknown
- 2015-04-29 MX MX2016014305A patent/MX362341B/es active IP Right Grant
- 2015-04-29 SG SG11201608161VA patent/SG11201608161VA/en unknown
- 2015-04-29 AP AP2016009485A patent/AP2016009485A0/en unknown
- 2015-04-29 PT PT157270984T patent/PT3137470T/pt unknown
- 2015-04-29 PL PL15727098T patent/PL3137470T3/pl unknown
- 2015-04-29 WO PCT/US2015/028264 patent/WO2015168269A1/en not_active Ceased
- 2015-04-29 JP JP2016565398A patent/JP6484253B2/ja active Active
- 2015-04-29 EA EA201692177A patent/EA030603B1/ru not_active IP Right Cessation
- 2015-04-30 AR ARP150101310A patent/AR100244A1/es unknown
- 2015-04-30 TW TW104113993A patent/TWI666212B/zh not_active IP Right Cessation
-
2016
- 2016-10-04 PH PH12016501966A patent/PH12016501966B1/en unknown
- 2016-10-13 IL IL248347A patent/IL248347B/en active IP Right Grant
- 2016-10-28 NI NI201600164A patent/NI201600164A/es unknown
- 2016-10-28 CL CL2016002751A patent/CL2016002751A1/es unknown
- 2016-10-31 GT GT201600233A patent/GT201600233A/es unknown
- 2016-11-01 DO DO2016000295A patent/DOP2016000295A/es unknown
- 2016-11-01 SV SV2016005311A patent/SV2016005311A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514838A5 (enExample) | ||
| JP2017514839A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2014508752A5 (enExample) | ||
| JP2019510796A5 (enExample) | ||
| JP2011207901A5 (enExample) | ||
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| JP2012525393A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2017516771A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2015511638A5 (enExample) | ||
| JP2015529235A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| RU2017105353A (ru) | Соединения | |
| JP2015508749A5 (enExample) | ||
| HRP20171808T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
| JP2016510326A5 (enExample) | ||
| JP2013506639A5 (enExample) | ||
| JP2017520613A5 (enExample) | ||
| JP2019511542A5 (enExample) | ||
| JP2017503798A5 (enExample) | ||
| JP2013525356A5 (enExample) |